The Problem: Fragmented EU Markets Create Pricing Cascades
Market access across 27+ EU countries — each with distinct HTA processes, pricing regulations, and reimbursement criteria — demands anticipating payer behavior. The Swiss BAG process adds another dimension. A pricing misstep in one reference pricing country can cascade across the entire EU, costing hundreds of millions in cumulative revenue over the product lifecycle.
The Solution: AI-Powered HTA Forecasting
Predictive models trained on 15 years of historical HTA decisions, epidemiological data, competitive landscapes, and economic indicators forecast approval probabilities and optimal price points per market. NLP extracts emerging decision patterns from published HTA reports. Bayesian updating refines predictions as new data — competitor pricing moves, updated clinical evidence — becomes available.
The Approach: Data-Driven Launch Sequencing
- 85% accuracy in predicting HTA outcomes across major EU markets
- Optimized launch sequencing that maximizes reference pricing advantages
- Data-driven pricing dossiers for Swiss BAG submissions and EU payer negotiations
- Scenario modeling for different pricing strategies and their cross-market implications
The difference between a well-sequenced and poorly sequenced EU launch can be worth €200M+ over the product lifecycle. Predictive analytics transforms this from intuition-based to data-driven decision-making.
How ANG Associates Can Help
ANG Associates helps market access teams leverage predictive analytics for smarter EU launch strategies. We combine AI expertise with deep understanding of HTA processes across Switzerland and the EU, enabling data-driven pricing and sequencing decisions. Our project management capability ensures the cross-functional coordination required between Market Access, Health Economics, Commercial Strategy, and Data Science teams to operationalize these insights into actionable launch plans.